Researchers find cancer-inhibiting compound under the sea

August 11, 2008

GAINESVILLE, Fla. - University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.

The UF-patented compound, largazole, is derived from cyanobacteria that grow on coral reefs. Researchers, who described results from early studies today (Aug. 7) at an international natural products scientific meeting in Athens, Greece, say it is one of the most promising they've found since the college's marine natural products laboratory was established three years ago.

An initial set of papers in the Journal of the American Chemical Society also has garnered the attention of other scientists, and the lab is racing to complete additional research. The molecule's natural chemical structure and ability to inhibit cancer cell growth were first described in the journal in February and the laboratory synthesis and description of the molecular basis for its anticancer activity appeared July 2.

"It's exciting because we've found a compound in nature that may one day surpass a currently marketed drug or could become the structural template for rationally designed drugs with improved selectivity," said Hendrik Luesch, Ph.D., an assistant professor in UF's department of medicinal chemistry and the study's principal investigator.

Largazole, discovered and named by Luesch for its Florida location and structural features, seeks out a family of enzymes called histone deacetylase, or HDAC. Overactivity of certain HDACs has been associated with several cancers such as prostate and colon tumors, and inhibiting HDACs can activate tumor-suppressor genes that have been silenced in these cancers.

Although scientists have been probing the depths of the ocean for marine products since the early 1960s, many pharmaceutical companies lost interest before researchers could deliver useful compounds because natural products were considered too costly and time-consuming to research and develop.

Many common medications, from pain relievers to cholesterol-reducing statins, stem from natural products that grow on the earth, but there is literally an ocean of compounds yet to be discovered in our seas. Only 14 marine natural products developed are in clinical trials today, Luesch said, and one drug recently approved in Europe is the first-ever marine-derived anticancer agent.

"Marine study is in its infancy," said William Fenical, Ph.D., a distinguished professor of oceanography and pharmaceutical sciences at the University of California, San Diego. "The ocean is a genetically distinct environment and the single, most diverse source of new molecules to be discovered."

The history of pharmacy traces its roots back thousands of years to plants growing on Earth's continents, used by ancient civilizations for medicinal purposes, Fenical added. Yet only in the past 30 years have scientists begun to explore the organisms in Earth's oceans, he said. Fewer than 30 labs exist worldwide and research dollars have only become available in the past 15 years.

HDACs are already targeted by a drug approved for cutaneous T-cell lymphoma manufactured by the global pharmaceutical company Merck & Co. Inc. However, UF's compound does not inhibit all HDACs equally, meaning a largazole-based drug might result in improved therapies and fewer side effects, Luesch said.

Since 2006, Luesch and his team of researchers have screened cyanobacteria provided by collaborator Valerie Paul, Ph.D., head scientist at the Smithsonian Marine Station in Fort Pierce. They check the samples for toxic activity against cancer cells and last year encountered one exceptionally potent extract - the one that ultimately yielded largazole.

To conduct further biological testing on the compound, Luesch and his team have been collaborating with Jiyong Hong, an assistant professor in the department of chemistry at Duke University, to replicate its natural structure and its actions in the laboratory.

Luesch said that within the next few months he plans to study whether largazole reduces or prevents tumor growth in mice.

Luesch has several other antitumor natural products from Atlantic and Pacific cyanobacteria in the pipeline.

"We have only scratched the surface of the chemical diversity in the ocean," Luesch said. "The opportunities for marine drug discovery are spectacular."

University of Florida

The growth of cancer cells: An inaugural lecture,
by Edward Holmes Cooper (Author)

Growth, Cancer, and the Cell Cycle: The Molecular, Cellular, and Developmental Biology
by Philip Skehan (Author), Susan J. Friedman (Author)

Research on cell growth, a fundamental biological process whose understanding may ultimately lead to the control of proliferative diseases such as cancer, is a rapidly moving field. The editors of this collection examine recent advances in this field.

It's true! Compound in Ginseng could end cancer.(algycon sapogenins prevent cancer cell growth): An article from: Women's Health Letter
by Soundview Publications (Publisher)

This digital document is an article from Women's Health Letter, published by Soundview Publications on March 1, 2003. The length of the article is 1909 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: It's true! Compound in Ginseng could end cancer.(algycon sapogenins prevent cancer cell growth)
Publication: Women's Health Letter (Newsletter)
Date: March 1, 2003
Publisher: Soundview Publications
Volume: 9 Issue: 3 Page: 1(5)

Distributed by Thomson...

Nucleic Acid Metabolism Cell Differentiation and Cancer Growth
by Edmund V. Cowdry (Author), Satimaru Seno (Author)

Tenascin: An Extracellular Matrix Protein in Cell Growth, Adhesion and Cancer (Molecular Biology Intelligence Unit)
by Prashanta Shrestha (Author), Masahiko Mori (Author)

Tenascin, a recently characterized extracellular matrix (ECM) protein which is expressed during embryonic and fetal development, wound healing and various benign and malignant tumors (but highly restricted in normal adult tissues) is believed to affect a number of cellular functions such as cellular growth, differentiation, adhesion and motility. It has been extensively studied in recent years to elucidate cellular phenomena that are associated with development, tissue regeneration and neoplastic growth and behavior. It may be a potential target in the treatment of cancers and other disorders. This book focuses mainly on tissue expression and the poorly known biological role of this ECM protein.

Handbook of Prostate Cancer Cell Research: Growth, Signalling and Survival (Cancer Etiology, Diagnosis and Treatment)
by Alan T. Meridith (Editor)

Prostate cancer is a disease in which cancer develops in the prostate, a gland in the male reproductive system. It occurs when cells of the prostate mutate and begin to multiply out of control. These cells may spread (metastasize) from the prostate to other parts of the body, especially the bones and lymph nodes. Prostate cancer may cause pain, difficulty in urinating, problems during sexual intercourse, erectile dysfunction and other symptoms. However those symptoms are present only in an advanced stage of the disease. Prostate cancer is the most common malignancy diagnosed in men and is the second leading cause of cancer deaths among males. Androgens play a major role in the development of prostate cancer since males castrated during childhood do not develop this disease. Another factor...

Molecular biology and differentiation of cancer cells (oncogenes, growth factors, receptors) (Lectures and symposia of the 14th International Cancer Congress, Budapest, August 21-27, 1986)
by Akademiai Kiado (Publisher)

Cell Growth (NATO Advanced Study Institutes Series)
by Claudio Nicolini (Editor)

Cell Growth and Cholesterol Esters (Molecular Biology Intelligence Unit)
by Alessandra Pani (Editor), Sandra Dessì (Editor)

This volume is devoted to cancer and atherosclerosis, two of the most important proliferative pathologies in the world today. This book provides a useful point of reference on the mechanisms that link cholesterol esters to cell proliferation, summarizing the latest advances both in basic science and clinical research. This book will be of undoubted value to biomedical students and teachers, as well as those actively engaged in research on cholesterol metabolism, cancer, and atherosclerosis.

Normal and Malignant Liver Cell Growth
by W.E. Fleig (Editor)

Although cell turnover in normal adult liver is extremely low, hepatic tissue is notorious for its almost infinite capacity to regenerate in cases of viral, toxic or traumatic damage. Hepatocellular carcinoma is one of the most frequent malignancies worldwide and causes more than a million deaths per year. The mechanisms governing normal proliferation and malignant transformation of liver cells are of utmost interest for the understanding of regeneration and hepatocarcinogenesis and for the development of new therapeutic strategies. Therefore, the International Falk Workshop held in Halle, Germany, on January 29-30 1998, focused on the issues of normal and malignant liver cell growth. Knowledge in this area of research has expanded rapidly during recent years. This book of...